bims-spamet Biomed News
on Spatial metabolomics of T cells
Issue of 2026–11–15
twelve papers selected by
Peio Azcoaga, Katholieke Universiteit te Leuven



  1. Immunity. 2026 Nov 10. pii: S1074-7613(26)00436-X. [Epub ahead of print]59(11): 2879-2881
      Metabolites can regulate T cell gene expression and effector function, but how changes in mitochondrial ATP production influence chromatin remodeling remains unclear. In a recent issue of Cell, Ng et al. demonstrate that D-α-hydroxybutyrate (DAHB) increases oxidative phosphorylation and phosphocreatine production, promoting chromatin accessibility and CD8+ T cell effector function to limit tumor growth.
    DOI:  https://doi.org/10.1016/j.immuni.2026.10.010
  2. Int J Mol Sci. 2026 Nov 05. pii: 9904. [Epub ahead of print]27(21):
      Ovarian cancer has an immunosuppressive microenvironment in which SPP1+ tumor-associated macrophages (TAMs) are linked to poor prognosis and immune evasion, yet their molecular features and metabolic mechanisms remain unclear. We therefore set out to determine whether SPP1 marks a discrete TAM subpopulation or a functional state in treatment-naïve high-grade serous ovarian cancer (HGSOC), to define the transcriptional and metabolic program that accompanies it, and to test whether local hypoxia is associated with it. Tumor-derived, treatment-naïve samples from three single-cell datasets (one lesion per patient; 47 patients) yielded 385,504 cells; Seurat v5 and Harmony were used for clustering, annotation, and batch correction. SPP1+/SPP1- macrophages were compared by differential expression, GO/KEGG/GSEA, metabolic scoring, and transcription factor inference, and the definition was retested with within-sample SPP1-high versus SPP1-low comparisons and with MSigDB Hallmark gene sets scored by two independent algorithms. Validation used Visium spatial transcriptomics (GSE263920), TCGA-OV (n = 429), CD8+ T cell exhaustion analysis, CellChat and a syngeneic ID8 model. Of 64,067 macrophages (16.62%), 82.0% were SPP1+; upregulated genes were enriched in glycolysis, monocyte migration and tissue remodeling, whereas MHC class II and neutrophil-related genes were downregulated. At the sample level, glycolysis, fatty acid synthesis and glutaminolysis scores were elevated and the cholesterol synthesis score was reduced, with no evidence of suppressed fatty acid oxidation or oxidative phosphorylation; HIF1A ranked 4th and NR1H3 3rd among 271 transcription factors. All 8 spatial sections showed positive hypoxia-SPP1 correlations, and hotspots showed elevated glycolysis, EMT, immunosuppression and macrophage scores. No robust association was found between SPP1+ TAM infiltration and CD8+ T cell exhaustion (p = 0.315). MDK-LRP1/SDC1 was the major macrophage-directed input. Immunofluorescence showed SPP1 immunoreactivity in a subset of CD68+ macrophages within HIF1α-rich areas of ID8 tumors, without CD8+PD-1+ T cell aggregation. SPP1+ TAMs therefore correspond to a hypoxic functional state with HIF1A activation, a glycolytic-lipogenic transcriptional program, reduced cholesterol synthesis gene expression and a reduced MHC class II program; protein-level and functional validation, and direct tests of HIF1A dependency, remain necessary.
    Keywords:  HIF1A; SPP1+ tumor-associated macrophages; hypoxia; metabolic reprogramming; ovarian cancer; single-cell transcriptomics; spatial transcriptomics
    DOI:  https://doi.org/10.3390/ijms27219904
  3. Cancer Lett. 2026 Nov 12. pii: S0304-3835(26)00738-X. [Epub ahead of print] 218974
      Perineural invasion (PNI) is a prominent feature of pancreatic cancer (PDAC) and is closely associated with tumor progression and poor prognosis. However, its spatial cellular architecture and underlying mechanisms remain incompletely understood. Here, we applied high-resolution spatial transcriptomics to construct a comprehensive atlas of the PNI microenvironment across distinct anatomical regions of intra and extra-pancreas. We observed that the Basal-like tumor subtype exhibited a higher propensity for PNI compared with the Classical subtype, a finding further supported by multiplex imaging on whole-mount histopathology. Comparative spatial analysis revealed distinct immune and stromal organization between tumor subtypes, with enrichment of M2-like macrophage potentially promoting epithelial cell migration in the vicinity of Basal-like tumors. In addition, we identified myofibroblast subset may promote Schwann cell activation and PNI-associated nerve injury was further accompanied by a shift toward inflammatory fibroblast polarization and features of CD8+ T cell exhaustion within the local microenvironment. Finally, spatial profiling indicated functional heterogeneity among tumor-associated Schwann cells, which may contribute to the tumor progression. Collectively, this study provides a spatially resolved view of the cellular and molecular landscape of PNI in PDAC and offers insights into Basal-specific neurotropic behavior and microenvironmental reorganization.
    Keywords:  Basal-like; Pancreatic cancer; Perineural invasion; Schwann cells; Whole-mount sectioning
    DOI:  https://doi.org/10.1016/j.canlet.2026.218974
  4. Immunity. 2026 Nov 10. pii: S1074-7613(26)00431-0. [Epub ahead of print]59(11): 3061-3080.e8
      Combination immunotherapy targeting the coinhibitory molecules TIGIT and PD-L1 promotes non-exhausted CD8+ T cell differentiation in cancer. Because anti-TIGIT efficacy requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action. Conventional dendritic cells (cDCs) were required for therapeutic efficacy. Transcriptional profiling of intratumoral myeloid cells revealed an FcγR+ cDC type-1 (cDC1)-like activation state characterized by elevated costimulatory ligands for CD28 (CD80/CD86) and CD226 (PVR) that was enriched in Fc-active anti-TIGIT combination-treated tumors. Therapy-expanded CD8+ T cells expressed CD28 and upregulated CD226 upon treatment. Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation. Type I interferon (IFN-I), induced through FcγR engagement, maintained and amplified the FcγR+ cDC1-like state, and exogenous IFN-I rescued anti-tumor immunity upon Fc-inert anti-TIGIT and anti-PD-L1 combination. Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.
    Keywords:  T cell activation; T cell differentiation; T cell exhaustion; checkpoint inhibition; costimulation; dendritic cells; immunotherapy; interferon signaling; myeloid cells; priming; tumor microenvironment
    DOI:  https://doi.org/10.1016/j.immuni.2026.10.005
  5. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2026 Nov;42(11): 1038-1043
      Mechanical immunity is an emerging research field in recent years that focuses on the interplay between mechanical forces and immune responses. As a mechanosensitive ion channel, Piezo1 can sense mechanical stimuli and modulate immune cells through associated signaling pathways. This review primarily elaborates on the mechanisms underlying the role of Piezo1 in innate and adaptive immune cells. At the level of innate immunity, in macrophages, Piezo1 senses mechanical cues such as extracellular matrix stiffness and cell membrane tension, thereby regulating macrophage polarization, phagocytic and bactericidal activity, and metabolic processes; in dendritic cells (DCs), Piezo1-mediated mechanical signals promote DC maturation and migration, and direct the immune response profile of DCs; in neutrophils (polymorphonuclear leukocytes, PMNs), Piezo1 plays a crucial role in regulating phagocytosis, angiogenesis promotion, and sterile thrombus formation. At the level of adaptive immunity, in CD8+ T cells, Piezo1 enables mechanical force sensing to suppress CD8+ T cell exhaustion, thereby enhancing their tumor-killing functions; in CD4+ T cells, Piezo1 specifically regulates the differentiation of T helper 9 (Th9) cells, providing a potential direction for anti-tumor therapy; in B cells, Piezo1 modulates the proliferation and differentiation of B cells into plasma cells, influences the production of corresponding antibodies, and plays a significant role in immune-related diseases. By reviewing the research on the regulatory mechanisms of Piezo1 in various immune cells, this paper aims to provide reference for the development of novel therapeutic strategies to treat immune-related diseases including autoimmune diseases, tumors and inflammation.
  6. iScience. 2026 Nov 20. 29(11): 118070
      T cell dysfunction limits the efficacy of cancer immunity, yet the molecular checkpoints that preserve T cell function within the tumor microenvironment are not fully understood. In this study, we identify a previously unrecognized, T cell-intrinsic role for nemo-like kinase (NLK) as a critical mediator of sustained anti-tumor responses. In our experiments, NLK emerged as a dual-function modulator: although NLK deficiency in CD4+ and CD8+ T cells increases proliferation and cytokine production in vitro via enhanced NFAT and AP-1 activation, its loss in vivo paradoxically impairs tumor control. In murine tumor models, NLK-deficient tumor-infiltrating T cells exhibit blunted effector activity resulting in accelerated tumor progression. Conversely, human chimeric antigen receptor (CAR) T cells that overexpress NLK demonstrate superior killing capacity toward target tumor cells. These findings establish NLK as an essential early brake on T cell activation while protecting against their chronic dysfunction, and reveal a molecular pathway that sustains anti-tumor immunity.
    Keywords:  T cell activation; T cell dysfunction; anti-tumor immunity; nemo-like kinase
    DOI:  https://doi.org/10.1016/j.isci.2026.118070
  7. Clin Immunol. 2026 Nov 12. pii: S1521-6616(26)00129-4. [Epub ahead of print] 110791
       BACKGROUND: Nasopharyngeal carcinoma (NPC) shows distinct distribution, and immunotherapy efficacy is limited by T cell dysfunction. Galectin-9 (LGALS9) has immunomodulatory roles, but its mechanism in NPC immune evasion remains unclear.
    METHODS: Using scRNA-seq data from GEO, we analyzed the NPC immune microenvironment and identified key ligand-receptor pairs. LGALS9 and CD44 expression were validated by immunohistochemistry, RT-qPCR, and western blot. CD8+ T cell function was assessed by flow cytometry, ELISA, and LDH release assay. The association between LGALS9 and CD44 was examined by coimmunoprecipitation, and a mouse model evaluated LGALS9 knockdown and CD44 antibody treatment.
    RESULTS: LGALS9 was upregulated in NPC and negatively correlated with CD8+ T cell infiltration. The LGALS9-CD44 association suppressed CD8+ T cell proliferation and activation, increasing PD1+ cells, decreasing GZMB+ cells and TNF-α/IFN-γ levels. Blocking this interaction restored T cell activity. LGALS9 knockdown inhibited tumor growth, and CD44 antibody blockade further potentiated the antitumor immune effect induced by LGALS9 knockdown.
    CONCLUSION: LGALS9 promotes NPC immune evasion through its association with CD44 on CD8+ T cells in vitro, and in vivo CD44 blockade is consistent with this mechanism, providing a rationale for targeting the LGALS9-CD44 axis.
    Keywords:  CD44; CD8(+) T cells; Immune evasion; LGALS9; Nasopharyngeal carcinoma
    DOI:  https://doi.org/10.1016/j.clim.2026.110791
  8. Nat Mater. 2026 Nov;25(11): 2055-2071
      Peritoneal metastasis (PM) and the resulting malignant tumour ascites characterize advanced gastrointestinal cancers, often leading to poor prognosis and limited response to current therapies. Single-cell analysis of patient-derived PM and malignant tumour ascites reveals an approximately 90% enrichment of TREM2+-tumour-associated macrophages, which drive CD8+ T cell dysfunction and tumour growth. Here we develop lipid nanoparticles encapsulating mRNA to reprogram these tumour-associated macrophages into chimeric antigen receptor macrophages targeting Claudin18.2-positive tumour ascites. The lipid nanoparticles incorporate a TREM2+ ligand to enhance the targeting of TREM2 macrophages. The piperazine-containing phosphoramide ionizable lipid synergizes with the TREM2 ligand to inhibit ligand dissociation, promoting TREM2 internalization and degradation via lysosomal and autophagosomal pathways. This inhibits AKT signalling and reprograms tumour-associated macrophages towards an antitumour phenotype, enhancing progenitor exhausted and effector memory CD8+ T cell responses, altering the PM transcriptome, and reducing immunosuppression in both malignant tumour ascites and tumours. Combined with PD-1 blockade, this therapy suppresses tumour growth and extends survival in mice, and with matching immunological effects in clinical samples, demonstrates its translational potential for PM immunotherapy.
    DOI:  https://doi.org/10.1038/s41563-026-02769-2
  9. Immunology. 2026 Nov 11.
      Over the past four decades, T cell exhaustion has been primarily associated with chronic infection and cancer and described as a late, adaptive response that limits immunopathology under chronic antigen exposure. Emerging evidence has revealed that exhausted T (Tex) cells are formed developmentally with distinct transcriptomic, epigenetic and phenotypic profiles, with progressive and hierarchical loss of effector functions. Recent reports show that exhaustion is not merely a late-stage phenomenon, but a multifaceted developmental trajectory that begins far earlier than previously thought. Intrinsic factors established at T cell priming synergize with extrinsic cues from the tissue microenvironment to drive T cell differentiation towards an exhausted state long before exhaustion becomes phenotypically fixed. This review presents an overview of recent knowledge that has reshaped our understanding of T cell exhaustion formation. Here, we discuss the genetic, epigenetic and metabolic determinants of T cell exhaustion, as well as the roles other soluble mediators and cell types may play in promoting exhaustion. Enhancing our understanding of early determinants of exhaustion has implications for the development and application of therapeutic strategies that adapt to the temporal evolution of exhaustion, which may be more effective than treatments aimed solely at reversing exhaustion.
    Keywords:  T cell differentiation; cancer immunology; epigenetic regulation; exhaustion; immunometabolism; infection; transcriptional control
    DOI:  https://doi.org/10.1111/imm.70223
  10. bioRxiv. 2026 Oct 21. pii: 2026.10.15.759372. [Epub ahead of print]
      Despite its promise in treating B cell malignancies, chimeric antigen receptor (CAR) T cell therapy remains limited by resistance mechanisms that impair CAR T cell stemness, persistence, and effector function. Here, we identified PRDM1 , which encodes the transcriptional repressor, BLIMP-1, as a crucial regulator of CAR T cell terminal differentiation and exhaustion. PRDM1 was highly enriched in exhausted-like tumor-infiltrating CAR T cells from lymphoma patients and in pre-infusion products from clinical non-responders. These findings link increased PRDM1 expression to CAR T cell dysfunction and poor clinical outcomes. Genetic deletion of PRDM1 significantly promoted CAR T cell proliferative capacity, memory differentiation and antitumor efficacy in both hematologic and solid tumor models. Mechanistically, PRDM1 deletion increased the activity of PGC1α, a transcriptional coactivator central to mitochondrial biogenesis and antioxidant capacity, thereby improving mitochondrial function, oxidative stress resistance, and metabolic reserve. Depletion of PGC1α attenuated the improved efficacy of PRDM1 -deficient CAR T cells, indicating an essential role for this pathway downstream of PRDM1 loss. Pharmacologic activation of the PPAR-PGC1α program with a clinically approved agonist, bezafibrate, enhanced CAR T cell antitumor activity without direct tumoricidal effects. Notably, transient exposure to bezafibrate during CAR T cell manufacturing was sufficient to confer durable treatment benefits. Together, our study defines a PRDM1 - PGC1Α axis that controls CAR T cell differentiation, mitochondrial fitness and therapeutic response, which provides a mechanistic and translational framework for advancing CAR T cell therapy across distinct tumor contexts.
    DOI:  https://doi.org/10.64898/2026.10.15.759372
  11. Cell Rep Med. 2026 Nov 12. pii: S2666-3791(26)00584-7. [Epub ahead of print] 103167
      Adoptive cell therapy (ACT) of tumor-specific T cells can improve survival in a subset of cancer patients. Current ACT approaches may be limited by using highly differentiated T cells, which can be inhibited by an immunosuppressive tumor microenvironment (TME). Here, we developed an approach to optimize ACT and used spatial transcriptomics to show how stem-like and effector CD8+ T cells differentially mediate tumor control following vaccination. Spatial transcriptomic profiling of the TME showed that ACT with stem-like T cells followed by intravenous vaccination prevented immune exclusion, increased infiltration of pro-inflammatory macrophages, and reprogrammed tumor cells to upregulate type I and type II IFN signaling gene programs, which were shown to be required for tumor control. The protective transcriptomic signature of the TME in this ACT model contained overlapping biomarkers with patients who responded to ACT therapy. This approach demonstrates synergy between transferred stem-like T cells and intravenous vaccination to transcriptionally remodel the TME and enhance tumor control.
    Keywords:  adoptive cell therapy; cancer immunotherapy; cancer vaccine; interferon signaling; intravenous vaccination; spatial transcriptomics; stem-like T cells; tumor microenvironment
    DOI:  https://doi.org/10.1016/j.xcrm.2026.103167
  12. Mol Ther. 2026 Nov 06. pii: S1525-0016(26)00936-6. [Epub ahead of print]
      Immune checkpoint blockade (ICB) therapy benefits only a subset of patients, and the role of non-T cells in ICB responses remains unclear. IL-1β has been reported to conduct controversial roles in antitumor immunity and ICB responsiveness. Here we show that IL-1β signaling is indispensable for the response to ICB therapy and for intratumoral tumor-specific CD8+ T cells. We hypothesized that ICB resistance is attributed to limited IL-1β inside tumor microenvironment (TME). We engineered mesenchymal stromal cells for the tumor-targeted inducible production of IL-1β-Fc (IL1βFc-EMSC) to study how this cytokine induces antitumor immunity inside the TME. Mechanistically, IL1βFc-EMSC treatment expands CD8+ T cells including Tcf1+PD1+ progenitor exhausted CD8+ T cells (Tpex) in the TME and enhances tumor-specific CD8+ T cell activation. MyD88 signaling in dendritic cells (DCs) by IL-1β might trigger type I IFN that are essential for intratumoral CD8+ T cell restimulation and systemic antitumor responses to eradicate both primary and distal tumors. Moreover, IL1βFc-EMSC treatment induced TIL reinvigoration overcomes ICB resistance in advanced tumors. Clinically, we uncovered a significant association between the formation of a spatially organized IL-1β-cDC1-Tpex axis and ICB responsiveness. Overall, tumor targeting IL-1β reshapes the TME by bridging innate and adaptive immunity to overcome ICB resistance.
    DOI:  https://doi.org/10.1016/j.ymthe.2026.11.003